drugset
drugset / Trial / NCT04481672

Intravenous Magnesium in Patients Receiving Cisplatin

NCT04481672 ↗

Phase 1 Completed 5 enrolled Dana-Farber Cancer Institute
NaSingle-groupOpen-labelSupportive care

Summary

This research study, is trying to determine the highest dose of magnesium that can be given safely to people with malignant mesothelioma receiving intraoperative chemotherapy with cisplatin who are at risk for acute kidney injury. The name(s) of the study drug involved in this study is * magnesium sulfate.

Timeline

Start
2021-07-30
Primary completion
2021-12-30
Completion
2021-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified — Intravenous

Indications

mesothelioma